I

(redirected from prostate cancer)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

I

Fifth letter of a Nasdaq stock symbol specifying that it is the third preferred bond of the company.

I

1. On a stock transaction table, a symbol indicating that a dividend was paid after a stock split.

2. A symbol appearing next to a bond listed on NASDAQ indicating that the bond is a company's third preferred bond. All NASDAQ listings use a four-letter abbreviation; if the letter "I" follows the abbreviation, this indicates that the security being traded is a third preferred bond.

i

Used in the dividend column of stock transaction tables to indicate that the dividend was paid after a stock dividend or split: Lehigh s.20i.
Mentioned in ?
References in periodicals archive ?
Blask notes a caveat to the new analysis: Diet can influence prostate cancer, and the Japanese study didn't determine whether the rotating-shift workers had less healthful diets than other men.
In many instances of acquired androgen independence in prostate cancer, the AR is modified such that it becomes sensitive to a variety of steroids, including nonandrogens.
More than one million men in the United States have prostate cancer, with an estimated 232,000 new cases of prostate cancer diagnosed each year.
Prostate cancer is the most common nonskin cancer in the country, and one in six males will get the disease.
At first we thought that ALA was associated with a higher risk of prostate cancer because men who consumed more ALA also consumed more meat," says Walter Willett, who chairs the nutrition department at the Harvard School of Public Health in Boston.
And, some prostate cancers grow so slowly and begin late enough in life that they may never be life threatening.
Image-guided brachytherapy alone and in combination with external beam radiation is a first-line therapy for patients with localized prostate cancer.
In addition to their work on the PCA3 technology in early-stage prostate cancer diagnosis, DiagnoCure is actively pursuing the development of a prototype test for lung cancer detection.
CLOUDED CRYSTAL BALL Currently, prognostic tools for prostate cancer use several clinical variables.
Today, the American Cancer Society recommends men undergo screening for prostate cancer starting at age 50.
The death count alone--31,500 lives lost every year--doesn't begin to measure the anxiety, misery, and pain caused by prostate cancer.